Citations

Clear

3138 citation(s) found for "Smith, AM".

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Gojo, Ivana , Pratz, Keith W. , McDevitt, Michael A. , Baer, Maria R. , Gore, Steven D. , Showel, Margaret M. , Gladstone, Douglas E. , Ji, Jiuping Jay, Wang, Lihua , Kinders, Robert J. , Pouquet, Marie , Walbi, Ismail A. , Poh, Weijie , Herman, James G. , Karnitz, Larry M., Chen, Alice P. , Karp, Judith E. , Kaufmann, Scott H. , Beumer, Jan Hendrik , Blackford, Amanda , Smith, B. Douglas , Carraway, Hetty E. , Levis, Mark J. , Dezern, Amy Elizabeth , Ji, Jiuping , Rudek, Michelle A. , Poh, Weijie

Mayo Clinic

Clinical Cancer Research | August 8, 2016 | Volume: 23 | Issue: 3 | Pages: 697-706

10.1158/1078-0432.ccr-16-0984 | PMID 27503200 Get It

Abstract Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patients with relapsed, refractory acute myeloid leukemia (AML) or AML arising from aggressive myeloid malignancies. Experimental Design: Patients received veliparib [20–200 mg once a day on day 1 and twice daily on days 4–12 in cycle 1 (days 1–8 in cycle ≥2)] and temozolomide [150–200 mg/m2 daily on days 3–9 in cycle 1 (days 1–5 in cycle ≥2)] every 28 to 56 days. Veliparib pharmacokinetics and pharmacodynamics [ability to inhibit poly(ADP-ribose) polymer (PAR) formation and induce H2AX phosphorylation] were assessed. Pretreatment levels of MGMT and PARP1 protein, methylation of the MGMT promoter, and integrity of the Fanconi anemia pathway were also examined. Results: Forty-eight patients were treated at seven dose levels. Dose-limiting toxicities were oral mucositis and esophagitis lasting >7 days. The MTD was veliparib 150 mg twice daily with temozolomide 200 mg/m2 daily. The complete response (CR) rate was 17% (8/48 patients). Veliparib exposure as well as inhibition of PAR polymer formation increased dose proportionately. A veliparib-induced increase in H2AX phosphorylation in CD34+ cells was observed in responders. Three of 4 patients with MGMT promoter methylation achieved CR. Conclusions: Veliparib plus temozolomide is well tolerated, with activity in advanced AML. Further evaluation of this regimen and of treatment-induced phosphorylation of H2AX and MGMT methylation as potential response predictors appears warranted. Clin Cancer Res; 23(3); 697–706. ©2016 AACR.
Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches
Martin, Jeremy , Carballido, Estrella M., Farhan, Bilal , Dutta, Rahul , Smith, Cody, Youssef, Ramy F. , Ahmed, Ahmed

Mayo Clinic

Arab Journal of Urology | August 3, 2016 | Volume: 14 | Issue: 3 | Pages: 183-191

10.1016/j.aju.2016.07.001 | PMID 27547458 Get It

Multiplex matrix network analysis of protein complexes in the human TCR signalosome
Smith, Stephen , Neier, Steven C. , Reed, Brendan , Davis, Tessa R. , Sinnwell, Jason P. , Eckel‐Passow, Jeanette E. , Sciallis, Gabriel F., Wieland, Carilyn N. , Torgerson, Rochelle R. , Gil, Diana , Neuhauser, Claudia , Schrum, Adam G. , Smith, Stephen E P, Reed, Brendan K, Neuhauser, Claudia , Schrum, Adam G , Sinnwell, Jason P

Mayo Clinic

Science Signaling | August 2, 2016 | Volume: 9 | Issue: 439 | Pages: No page available

10.1126/scisignal.aad7279 | PMID 27485017 Get It

A multiplex antibody-mediated capture technique reveals patient-specific protein complexes.
Design and Methodological Considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida
Cheng, Earl Y. , Austin, J. Christopher , Baum, Michelle A. , Gargollo, Patricio C. , Grady, Richard W., Herron, Adrienne R. , Kim, Steven S., King, Shelly , Koh, Chester J. , Paramsothy, Pangaja , Raman, Lisa, Smith, Kathryn , Tanaka, Stacy T. , Thibadeau, Judy , Walker, William O., Wallis, M. Chad , Wiener, John S. , Joseph, David B. , Routh, Jonathan C. , Schechter, Michael S.

Mayo Clinic

Journal of Urology | July 28, 2016 | Volume: 196 | Issue: 6 | Pages: 1728-1734

10.1016/j.juro.2016.07.081 | PMID 27475969 Get It

Whole Exome Sequencing, Familial Genomic Triangulation, and Systems Biology Converge to Identify a Novel Nonsense Mutation inTAB2-encoded TGF-beta Activated Kinase 1 in a Child with Polyvalvular Syndrome
Ackerman, Jaeger P., Smestad, John , Tester, David J. , Qureshi, M. Yasir , Crabb, Beau, Mendelsohn, Nancy J., Ackerman, Michael J. , Smestad, John A, Qureshi, Muhammad Y , Smestad, John

Mayo Clinic

Congenital Heart Disease | July 25, 2016 | Volume: 11 | Issue: 5 | Pages: 452-461

10.1111/chd.12400 | PMID 27452334 Get It

Molecular Validation of Chondrogenic Differentiation and Hypoxia Responsiveness of Platelet-Lysate Expanded Adipose Tissue–Derived Human Mesenchymal Stromal Cells
Galeano‐Garces, Catalina , Camilleri, Emily T. , Riester, Scott M. , Dudakovic, Amel , Qu, Wenchun , Smith, Jay , Dietz, Allan B. , Im, Hee‐Jeong, Krych, Aaron J. , Larson, A. Noelle , Karperien, Marcel , Wijnen, André J. van , Camilleri, Emily , Larson, Dirk R. , van Wijnen, Andre J, Im, Hee‐Jeong , van Wijnen, Andre J , Krych, Aaron J , Larson, A Noelle , Dietz, Allan B , Camilleri, Emily

Mayo Clinic

CARTILAGE | July 22, 2016 | Volume: 8 | Issue: 3 | Pages: 283-299

10.1177/1947603516659344 | PMID 28618870 Get It

Objective: To determine the optimal environmental conditions for chondrogenic differentiation of human adipose tissue–derived mesenchymal stromal/stem cells (AMSCs). In this investigation we specifically investigate the role of oxygen tension and 3-dimensional (3D) culture systems. Design: Both AMSCs and primary human chondrocytes were cultured for 21 days in chondrogenic media under normoxic (21% oxygen) or hypoxic (2% oxygen) conditions using 2 distinct 3D culture methods (high-density pellets and poly-ε-caprolactone [PCL] scaffolds). Histologic analysis of chondro-pellets and the expression of chondrocyte-related genes as measured by reverse transcriptase quantitative polymerase chain reaction were used to evaluate the efficiency of differentiation. Results: AMSCs are capable of expressing established cartilage markers including COL2A1, ACAN, and DCN when grown in chondrogenic differentiation media as determined by gene expression and histologic analysis of cartilage markers. Expression of several cartilage-related genes was enhanced by low oxygen tension, including ACAN and HAPLN1. The pellet culture environment also promoted the expression of hypoxia-inducible cartilage markers compared with cells grown on 3D scaffolds. Conclusions: Cell type–specific effects of low oxygen and 3D environments indicate that mesenchymal cell fate and differentiation potential is remarkably sensitive to oxygen. Genetic programming of AMSCs to a chondrocytic phenotype is effective under hypoxic conditions as evidenced by increased expression of cartilage-related biomarkers and biosynthesis of a glycosaminoglycan-positive matrix. Lower local oxygen levels within cartilage pellets may be a significant driver of chondrogenic differentiation.
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Chen, Robert , Gopal, Ajay K. , Smith, Scott E. , Ansell, Stephen M. , Rosenblatt, Joseph D. , Engert, Andreas , Larsen, Emily K., Huebner, Dirk, Fong, Abraham, Younes, Anas , Savage, Kerry J. , Connors, Joseph M. , Gopal, Ajay

Mayo Clinic

Blood | July 18, 2016 | Volume: 128 | Issue: 12 | Pages: 1562-1566

10.1182/blood-2016-02-699850 | PMID 27432875 Get It

Key Points A total of 38% of patients who achieved CR (13 of 34) on brentuximab vedotin have remained in remission for >5 years and may be cured. Nine of the 13 patients (9% of all enrolled patients) have remained in long-term remission without a consolidative allogeneic transplant.
Shared Genetic Risk Factors of Intracranial, Abdominal, and Thoracic Aneurysms
Hof, Femke N. G. van ’t, Ruigrok, Ynte M. , Lee, Cue Hyunkyu , Ripke, Stephan , Anderson, Graig, Baas, Annette F., Blankensteijn, Jan D. , Böttinger, Erwin P. , Bown, Matthew J. , Broderick, Joseph P., Bijlenga, Philippe , Crosslin, David R. , Ebeling, Christian , Eriksson, Johan G. , Fornage, Myriam , Foroud, Tatiana, Fraunberg, Mikael von und zu , Friedrich, Christoph M. , Gaál, Emília Ilona, Gottesman, Omri, Guo, Dongchuan , Harrison, Seamus C. , Hernesniemi, Juha , Hofman, Albert , Inoue, Ituro , Jääskeläinen, Juha E. , Kiemeney, Lambertus A. , Kivisaari, Riku , Ko, Nerissa , Koskinen, Seppo, Kubo, Michiaki , Kuivaniemi, Helena , Laakso, Aki , Lehto, Hanna, LeMaire, Scott A. , Malinowski, Jennifer , McCarty, Catherine A. , Mosley, Thomas H., Nakaoka, Hirofumi , Peissig, Peggy , Pera, Joanna , Rasmussen‐Torvik, Laura J. , Ritchie, Marylyn D. , Rivadeneira, Fernando , Rij, André M. van , Santos‐Cortez, Regie Lyn P., Saratzis, Athanasios , Słowik, Agnieszka , Tromp, Gerard , Uitterlinden, André G. , Vermeulen, Sita H. , Wang, Gao T., Han, Buhm , Bakker, Paul I. W. de , Verissimo, Ana Raquel, Wright, Benjamin J., Bumpstead, Suzannah, Grétarsdóttir, Sólveig , Badger, Stephen A., Child, Anne H. , Cockerill, Gillian, Hafez, Hany , Futers, Simon , Sohrabi, Soroush, Smith, Alberto, Thompson, Matthew M., Bockxmeer, Frank M. van, Matthíasson, Stefán E., Þorsteinsdóttir, Unnur , Graaf, Jacqueline de , Palmen, Jutta, Lindholt, Jes S. , Bradley, Declan , Waltham, Matthew, Gwilliam, Rhian, Golledge, Jonathan , Eriksson, Per , Stefánsson, Kāri , Thompson, John R., Humphries, Steve E. , Sayers, Robert D., Deloukas, Panos , Samani, Nilesh J. , Phillip, L. Victoria, Hill, Geraldine B., Williams, Michael , Thomson, Ian , Krysa, Jo, Wilkins, Gerard , Vasudevan, Thodor M., Lewis, David R. , Blair, Ross D., Hill, Andrew A., de Andrade, Mariza, Ripke, Stephan , Andrade, Mariza de , Broderick, Joseph, Carrell, David , Crawford, Dana C. , Jones, Gregory T. , Kullo, Iftikhar J. , Kurki, Mitja , Lai, Dongbing , Leal, Suzanne M. , Low, Siew‐Kee , Milewicz, Dianna M. , Nakamura, Yusuke , Niemela, Mika R. , Pacheco, Jennifer A. , Takahashi, Atsushi , Verma, Shefali S. , Rinkel, Gabriël J.E. , Clough, Rachel E. , Scott, D. Julian A., Þorleifsson, Guðmar , Teijink, Joep A.W. , Wijmenga, Cisca , Smith, Andrew J P , Edkins, Sarah , Hunt, Sarah E , Potter, Simon , Norman, Paul E , Powell, Janet T. , Merriman, Tony Raymond , Kiemeney, Lambertus A , Bijlenga, Philippe , Lindholt, Jes Sanddal , Malinowski, Jennnifer , Rasmussen-Torvik, Laura J , Eriksson, Per

Mayo Clinic

Journal of the American Heart Association | July 15, 2016 | Volume: 5 | Issue: 7 | Pages: No page available

10.1161/jaha.115.002603 | PMID 27418160 Get It

Background Intracranial aneurysms ( IAs ), abdominal aortic aneurysms ( AAAs ), and thoracic aortic aneurysms ( TAAs ) all have a familial predisposition. Given that aneurysm types are known to co‐occur, we hypothesized that there may be shared genetic risk factors for IAs , AAAs, and TAAs . Methods and Results We performed a mega‐analysis of 1000 Genomes Project‐imputed genome‐wide association study ( GWAS ) data of 4 previously published aneurysm cohorts: 2 IA cohorts (in total 1516 cases, 4305 controls), 1 AAA cohort (818 cases, 3004 controls), and 1 TAA cohort (760 cases, 2212 controls), and observed associations of 4 known IA , AAA , and/or TAA risk loci (9p21, 18q11, 15q21, and 2q33) with consistent effect directions in all 4 cohorts. We calculated polygenic scores based on IA ‐, AAA ‐, and TAA ‐associated SNP s and tested these scores for association to case‐control status in the other aneurysm cohorts; this revealed no shared polygenic effects. Similarly, linkage disequilibrium–score regression analyses did not show significant correlations between any pair of aneurysm subtypes. Last, we evaluated the evidence for 14 previously published aneurysm risk single‐nucleotide polymorphisms through collaboration in extended aneurysm cohorts, with a total of 6548 cases and 16 843 controls ( IA ) and 4391 cases and 37 904 controls ( AAA ), and found nominally significant associations for IA risk locus 18q11 near RBBP 8 to AAA (odds ratio [ OR ]=1.11; P =4.1×10 −5 ) and for TAA risk locus 15q21 near FBN 1 to AAA ( OR =1.07; P =1.1×10 −3 ). Conclusions Although there was no evidence for polygenic overlap between IAs , AAAs , and TAAs , we found nominally significant effects of two established risk loci for IAs and TAAs in AAAs . These two loci will require further replication.
Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization
Fratzl‐Zelman, Nadja , Barnes, Aileen M. , Weis, MaryAnn , Carter, Erin , Hefferan, Theresa E., Perino, Giorgio , Chang, Weizhong , Smith, Peter A. , Roschger, Paul, Klaushofer, Klaus, Glorieux, Francis H. , Eyre, David R. , Raggio, Cathleen , Rauch, Frank , Marini, Joan C. , Carter, Erin M.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 6, 2016 | Volume: 101 | Issue: 9 | Pages: 3516-3525

10.1210/jc.2016-1334 | PMID 27383115 Get It

Abstract Context: Type VIII osteogenesis imperfecta (OI; OMIM 601915) is a recessive form of lethal or severe OI caused by null mutations in P3H1, which encodes prolyl 3-hydroxylase 1. Objectives: Clinical and bone material description of non-lethal type VIII OI. Design: Natural history study of type VIII OI. Setting: Pediatric academic research centers. Patients: Five patients with non-lethal type VIII OI, and one patient with lethal type VIII OI. Interventions: None. Main Outcome Measures: Clinical examinations included bone mineral density, radiographs, and serum and urinary metabolites. Bone biopsy samples were analyzed for histomorphometry and bone mineral density distribution by quantitative backscattered electron imaging microscopy. Collagen biochemistry was examined by mass spectrometry, and collagen fibrils were examined by transmission electron microscopy. Results: Type VIII OI patients have extreme growth deficiency, an L1–L4 areal bone mineral density Z-score of −5 to −6, and normal bone formation markers. Collagen from bone and skin tissue and cultured osteoblasts and fibroblasts have nearly absent 3-hydroxylation (1–4%). Collagen fibrils showed abnormal diameters and irregular borders. Bone histomorphometry revealed decreased cortical width and very thin trabeculae with patches of increased osteoid, although the overall osteoid surface was normal. Quantitative backscattered electron imaging showed increased matrix mineralization of cortical and trabecular bone, typical of other OI types. However, the proportion of bone with low mineralization was increased in type VIII OI bone, compared to type VII OI. Conclusions: P3H1 is the unique enzyme responsible for collagen 3-hydroxylation in skin and bone. Bone from non-lethal type VIII OI children is similar to type VII, especially bone matrix hypermineralization, but it has distinctive features including extremely thin trabeculae, focal osteoid accumulation, and an increased proportion of low mineralized bone.